Driven by continuous technological breakthroughs, gradual improvement in regulatory pathways, and increasing capital investment, the internal gene therapy industry is accelerating its transition from an early exploration phase to commercialization. This is especially true in China.Against the backdrop of the '15th Five-Year Plan' listing biomanufacturing as a core direction for strategic emerging industries and gene therapy being identified as a key area requiring 'key progress', gene therapy has risen to become an important component in building national bioeconomic competitiveness.
However, the industry still faces systemic challenges such as complex production processes, insufficient large-scale production capacity, high hollowing-out rates and cost pressures, long-term data to be verified, and an imperfect payment system. Based on continuous research and accumulation in the field of gene therapy within the body, Frost & Sullivan (frost &Frost & Sullivan, hereinafter referred to as 'Frost & Sullivan', plans to officially release the '2026 Global In Vivo Gene Therapy Industry Development Blue Book' in August 2026, and sincerely invites companies in the industry to participate together to promote industry development.
Research content
This time,The 'Global In Vivo Gene Therapy Industry Development Blue Book 2026' will conduct a systematic study focusing on the development panorama and key links of the in vivo gene therapy industry. The report will define the core concepts and technical classifications of in vivo gene therapy, starting from different treatment strategies such as gene replacement, gene augmentation, and gene editing. Combining two major delivery systems, viral vectors and non-viral vectors, it will compare and analyze their technical principles, applicable scenarios, and differentiated characteristics, thereby constructing an overall cognitive foundation for the in vivo gene therapy technology system.
At the industrial chain level, the report systematically disassembles the complete industrial chain and key technology system of in vivo gene therapy from upstream production to downstream purification, with a focus on analyzing cell line development and transfection./Optimize core process links such as infection system and chromatographic purification, and conduct in-depth analysis of key bottlenecks including low yields, high empty capsule rates, difficulties in scale-up, high purification costs, complex quality control methodologies, and the absence of unified standards.
In terms of commercialization and value realization, the report will analyze the key path from clinical validation to commercialization implementation of in vivo gene therapies. It will focus on core indication areas such as ophthalmology, blood diseases, central nervous system, and cardiovascular diseases. The report will sort out the structural distribution of globally marketed products and research pipelines, and analyze their cost substitution logic and pricing basis based on long-term efficacy from the perspective of health economics. It will also explore the commercialization feasibility path of in vivo gene therapies by combining multiple payment models such as installment payments, risk sharing, and commercial insurance.
In addition, the report will also analyze the core driving factors and future trends of the development of the gene therapy industry globally and in China, systematically exploringAgainst the backdrop of the '15th Five-Year Plan', optimized delivery systems, upgraded gene editing technology, AI-empowered process quality control, increased capital investment, expansion of indications from rare diseases to chronic diseases, optimized regulatory pathways, and rising demand for precision medicine, the industry's long-term development direction and growth potential are multifaceted. Finally, the report will conduct case studies on representative key enterprises in the global intravenous gene therapy field, systematically sort out their development history and strategic positioning, comprehensively present their latest product pipeline layout and clinical progress, and deeply analyze the therapeutic advantages of core products in different sub-indices. At the same time, combining key dimensions such as delivery efficiency, production technology, and safety, it will dissect the main challenges and competitive advantages they face in the process of technical realization and industrialization.
Frost & Sullivan will collaborate with multiple stakeholders within the industry chain to participate in the research and release process. Under a professional research framework, they will form a rational expression of industry development and accumulate consensus, jointly promoting the long-term healthy development of the global gene therapy industry.
Release Highlights
1. Increase the propagation potential
"TheThe 'Global In Vivo Gene Therapy Industry Development Blue Book 2026' will be officially released at the 20th Global Growth and Innovation Leadership Summit of Frost & Sullivan in early August 2026. The blue book will be published through the official Frost & Sullivan website, the global media matrix of Frost & Sullivan, and vertical media channels in the field of gene therapy, and will also be widely disseminated on mainstream financial platforms. The report will systematically present the core strengths of enterprises in terms of technology layout, product capabilities, and industry collaboration, enhancing market recognition and trust in the professional strength of enterprises, improving industry influence and brand awareness, and providing a window for cooperative enterprises to voice their opinions with authority and achieve highly focused communication.
The English version will also be made available simultaneously on globally renowned news agencies (such as The Associated Press), mainstream financial media (such as Yahoo Finance), top North American financial media and websites (Business Insider, Dow Jones Market Watch,Benzinga, Wall Street Insider, and other sources, as well as top media from various regions including Europe, Japan and South Korea, Southeast Asia, and the Belt and Road Initiative. This further expands the brand voice and influence of the enterprise in the international market, effectively helping global companies in the field of gene therapy advance product development and layout.
2.Establish ecological connectivity
Through the Blue Book Research and Publication Platform, we promote in-depth exchanges and cooperation docking among enterprises within the context of the industrial chain.
Under the industry development framework, it demonstrates the enterprise's positioning and competitive advantages in the industrial chain, strengthens the cognitive connection with upstream and downstream enterprises, partners, and relevant institutions, promotes technological collaboration and resource integration, and creates a foundation for subsequent cooperation.
3.Establish industry image
The Blue Book will objectively present the business situation and industry status of enterprises from dimensions such as industry development stages, competitive landscape, and trend analysis.
By systematically presenting research content, we aim to strengthen the professional image and strategic positioning of enterprises in gene therapy within the industry, enhancing their recognition and influence both in the internal and external markets.
4.Overwrite capital market concerns
Relying on Frost & Sullivan's network of partners and followers in the primary and secondary markets, the release of research findings helps to enhance a company's visibility and attention in the capital market.
By disseminating research findings, we aim to attract the attention of potential investors and related institutions, and to promote effective communication with the capital market.
5.Lay the foundation for long-term cooperation
The in-depth exchanges formed through the Blue Book cooperation help both parties further explore potential cooperation in brand communication, investment and financing consulting, growth strategies, etc., laying a foundation for long-term follow-up cooperation.
